Total Payments
$668,104
2024 Payments
$47,163
Companies
13
Transactions
843
Medicare Patients
771
Medicare Billing
$136,874
Payment Breakdown by Category
Other$550,978 (82.5%)
Travel$86,786 (13.0%)
Food & Beverage$16,899 (2.5%)
Consulting$11,360 (1.7%)
Research$1,788 (0.3%)
Education$294.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $324,295 | 187 | 48.5% |
| Honoraria | $226,683 | 83 | 33.9% |
| Travel and Lodging | $86,786 | 323 | 13.0% |
| Food and Beverage | $16,899 | 224 | 2.5% |
| Consulting Fee | $11,360 | 8 | 1.7% |
| Unspecified | $1,788 | 12 | 0.3% |
| Education | $294.00 | 6 | 0.0% |
Payments by Type
General
$666,317
831 transactions
Research
$1,788
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SK Life Science, Inc. | $257,938 | 226 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $187,555 | 262 | $0 (2022) |
| UCB, Inc. | $82,465 | 151 | $0 (2023) |
| Greenwich Biosciences, Inc. | $74,467 | 95 | $0 (2021) |
| EISAI INC. | $39,107 | 53 | $0 (2022) |
| LivaNova USA, Inc. | $21,276 | 27 | $0 (2024) |
| Biogen, Inc. | $1,788 | 12 | $0 (2017) |
| JAZZ PHARMACEUTICALS INC. | $1,457 | 2 | $0 (2022) |
| NEUROPACE, INC. | $1,245 | 6 | $0 (2018) |
| Neurelis, Inc. | $483.20 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,163 | 40 | SK Life Science, Inc. ($31,062) |
| 2023 | $44,192 | 53 | SK Life Science, Inc. ($43,749) |
| 2022 | $148,389 | 142 | SK Life Science, Inc. ($122,206) |
| 2021 | $72,610 | 68 | SK Life Science, Inc. ($55,722) |
| 2020 | $22,804 | 27 | Eisai Inc. ($13,631) |
| 2019 | $125,763 | 163 | Greenwich Biosciences, Inc. ($71,021) |
| 2018 | $97,087 | 167 | Sunovion Pharmaceuticals Inc. ($61,610) |
| 2017 | $110,096 | 183 | Sunovion Pharmaceuticals Inc. ($75,926) |
All Payment Transactions
843 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $9,100.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $140.35 | General |
| Category: Neurology | ||||||
| 12/08/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $140.81 | General |
| Category: EPILEPSY | ||||||
| 12/08/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $79.86 | General |
| 11/25/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $468.48 | General |
| Category: Neurology | ||||||
| 10/29/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,409.00 | General |
| Category: Neurology | ||||||
| 10/29/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $64.20 | General |
| Category: Neurology | ||||||
| 10/29/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $59.65 | General |
| Category: Neurology | ||||||
| 10/29/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $59.00 | General |
| Category: Neurology | ||||||
| 10/24/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| Category: Neurology | ||||||
| 10/24/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $100.91 | General |
| Category: Neurology | ||||||
| 09/26/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: EPILEPSY | ||||||
| 09/21/2024 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $234.60 | General |
| Category: Neurology | ||||||
| 09/20/2024 | LivaNova USA, Inc. | VNS Therapy (Device) | Travel and Lodging | In-kind items and services | $483.67 | General |
| Category: Neurology | ||||||
| 09/20/2024 | LivaNova USA, Inc. | VNS Therapy (Device) | Travel and Lodging | In-kind items and services | $414.00 | General |
| Category: Neurology | ||||||
| 09/20/2024 | LivaNova USA, Inc. | VNS Therapy (Device) | Travel and Lodging | In-kind items and services | $237.63 | General |
| Category: Neurology | ||||||
| 09/20/2024 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $153.45 | General |
| Category: Neurology | ||||||
| 09/17/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $4,200.00 | General |
| Category: Neurology | ||||||
| 09/17/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $486.96 | General |
| Category: Neurology | ||||||
| 09/17/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | Cash or cash equivalent | $247.41 | General |
| Category: Neurology | ||||||
| 09/17/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Travel and Lodging | In-kind items and services | $208.16 | General |
| Category: Neurology | ||||||
| 09/17/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $126.37 | General |
| Category: Neurology | ||||||
| 09/05/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,202.00 | General |
| Category: Neurology | ||||||
| 05/31/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $1,400.00 | General |
| Category: Neurology | ||||||
| 05/23/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $700.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biogen, Inc. | $1,788 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 241 | 348 | $129,657 | $40,246 |
| 2022 | 7 | 151 | 247 | $86,095 | $30,626 |
| 2021 | 10 | 231 | 351 | $142,235 | $42,588 |
| 2020 | 6 | 148 | 194 | $83,544 | $23,414 |
Total Patients
771
Total Services
1,140
Medicare Billing
$136,874
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 64 | 123 | $65,682 | $22,356 | 34.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 46 | $14,490 | $5,870 | 40.5% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 68 | 82 | $13,694 | $4,076 | 29.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 34 | $5,950 | $2,332 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 21 | $5,040 | $1,874 | 37.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $7,320 | $1,709 | 23.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 15 | $3,765 | $1,568 | 41.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 12 | 12 | $13,716 | $460.21 | 3.4% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 35 | 86 | $45,924 | $15,995 | 34.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $10,736 | $3,904 | 36.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 55 | $9,625 | $3,474 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 18 | $5,670 | $2,722 | 48.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 22 | $5,280 | $1,706 | 32.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 18 | $4,518 | $1,474 | 32.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 26 | 26 | $4,342 | $1,351 | 31.1% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 52 | 111 | $57,774 | $20,952 | 36.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 27 | $13,176 | $4,915 | 37.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 24 | $7,560 | $3,514 | 46.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 52 | $9,100 | $3,396 | 37.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 30 | $7,200 | $2,708 | 37.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 28 | $7,028 | $2,626 | 37.4% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2021 | 42 | 45 | $10,959 | $2,391 | 21.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $2,849 | $913.28 | 32.1% |
| 95812 | Measurement of brain wave (eeg) activity, 41-60 minutes | Facility | 2021 | 12 | 12 | $14,610 | $594.48 | 4.1% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 11 | 11 | $11,979 | $580.47 | 4.8% |
About Dr. Mohamad Koubeissi, MD
Dr. Mohamad Koubeissi, MD is a Epilepsy healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548368970.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohamad Koubeissi, MD has received a total of $668,104 in payments from pharmaceutical and medical device companies, with $47,163 received in 2024. These payments were reported across 843 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($324,295).
As a Medicare-enrolled provider, Koubeissi has provided services to 771 Medicare beneficiaries, totaling 1,140 services with total Medicare billing of $136,874. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Epilepsy
- Other Specialties Neurology
- Location Washington, DC
- Active Since 09/20/2006
- Last Updated 04/01/2025
- Taxonomy Code 2084E0001X
- Entity Type Individual
- NPI Number 1548368970
Products in Payments
- XCOPRI (Drug) $251,965
- APTIOM (Drug) $187,555
- Epidiolex (Drug) $74,467
- Briviact (Drug) $70,335
- Fycompa (Drug) $39,107
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $13,077
- Vimpat (Drug) $9,242
- Cenobamate (Drug) $5,200
- VNS - Sentiva (Device) $4,170
- VNS Therapy (Device) $4,029
- TYSABRI (Biological) $1,788
- EPIDIOLEX (Drug) $1,457
- RNS System (Device) $1,245
- VALTOCO (Drug) $483.20
- SABRIL (Drug) $125.00
- ONFI (Drug) $105.93
- PERCEPT PC BRAINSENSE (Device) $48.18
- TROKENDI XR (Drug) $45.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.